Latest Research, Industry, Medical and Scientific News
North African start-up, ProvenMed, has been named startup winner of the MIT Arab Startup competition 11th edition Award. ProvenMed Co-Founder & CEO, Souheil Guessoum received the award at the ceremony chaired by the chair of the board of MIT Enterprise Forum Pan Arab, Hala Fadel. Promoted by MIT Enterprise Forum, the Arab Startup competition Awards aim to create an ecosystem based on the most outstanding startups from across the Arab countries. In addition to demonstration of innovation and a viable business model, winners are selected based on their contribution to advancing sustainability, active social responsibility engagement and participation in Arab projects and partnerships. The 11th edition competition took place in Sultanate Oman on 19th of April 2018 and was supported by Community Jameel, a founding partner for 10 consecutive years. As a local support and engagement in the Sultanate of Oman, strategic partners this year include Riyada, the competition’s governmental backbone, and Omantel, the key contributor and supporter. Regionally, partners also include Zain Group, the competition’s digital partner. ProvenMed, based in Tunis, was founded in 2017 and currently at the commercialization stage of its flagship innovative product ActivGo™ for men. Read more.
Source: Zawya, April 24, 2018
LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”). After the previously announced completion of the tender offer for all of the outstanding shares of Cogentix, LABORIE completed the second step merger under Delaware law, resulting in Cogentix becoming a wholly owned subsidiary of Parent. At the effective time of the merger, all shares of Cogentix common stock not purchased in the tender offer (excluding those shares for which holders properly exercised appraisal rights under Delaware law and those held by Cogentix) were converted into the right to receive US$3.85, net to the seller in cash without interest thereon and subject to any required withholding tax, which is the same price that was paid for shares of Cogentix common stock purchased in the tender offer. Cogentix common stock will no longer be listed on the Nasdaq Capital Market or any other securities exchange. Read more.
Source: The Virginian-Pilot, April 23, 2018
A new consensus-based study has for the first time identified what a set of outcome measures and key performance indicators (KPIs) might look like for toileting and containment strategies, helping patients and professionals in the delivery of incontinence management. These findings were launched yesterday in Rome, Italy, at the 7th Global Forum on Incontinence (GFI) on the topic of ‘Driving outcomes in continence care – creating a win-win for patients, carers and health systems’. The study, ‘Measuring outcomes to improve the management of continence care’, was initiated by Essity, a leading global hygiene and health company, led by an expert panel and facilitated by KPMG’s Global Strategy Group. Read more.
Source: Health Europa, April 19, 2018
Both tibial nerve stimulation (TNS) and pelvic floor muscle training (PFMT) can improve sleep quality in women with nocturia, according to new study findings. In a randomized trial, 40 women with self-reported nocturia were blindly assigned to transcutaneous electrical TNS or PFMT with behavioral therapy for 30 minutes each week for 3 months. PFMT inhibits detrusor contraction, and TNS eases lower urinary tract symptoms. Women with neurogenic bladder or on antimuscarinic or antidiuretic therapy were among the excluded patients. Read more.
Source: Renal and Urology News, April 11, 2018
Most of us don’t have to give much thought to the mechanics of going to the bathroom. Our bodies tell our brains when we have to go, and our brains tell our bodies when it’s acceptable to do so. But millions of people with incontinence have to cope numerous times a day with the reality that the brain-to-body messaging they once took for granted will never operate normally again. In a small office building in Fort Lauderdale, inventor Peter H. Sayet says he’s close to marketing a device that will enable incontinence sufferers to regain control of their urinary functions. Sayet is president and CEO of Precision Medical Devices Inc., which he founded in 1998. In the past two decades, the company has secured nine patents and spent $5 million raised from about 200 investors through private-placement stock offerings to develop a Bluetooth-operated bionic sphincter controller, which he calls the Flow Control Device. Read more.
Source: Sun Sentinel, April 9, 2018
More sensitive cultivation methods and precise 16S rRNA gene sequencing techniques have revealed that the human bladder hosts a significant microbiome and those diverse bacteria inside the bladder impact pediatric urologic diseases. As recently as one decade ago, the human bladder was thought to be a sterile landscape. In recent years that view has shifted radically, opening brand-new fields of research aimed at clarifying the role the microbiome plays in common urologic diseases that affect children, according to a review article published online Feb. 22, 2018, by Current Urology Reports. “There is a growing appreciation for the role of diverse bacteria in contributing to improved health as well as triggering disease processes or exacerbating illness,” says Michael H. Hsieh, M.D., Ph.D., director of the Clinic for Adolescent and Adult Pediatric Onset Urology (CAPITUL) at Children’s National Health System and study senior author. Read more.
Source: Medical Xpress, APril 5, 2018